PEPeter Eriksson

Peter Eriksson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter Eriksson has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trends in Congenital Heart Disease Hospitalizations: What Nearly 50 Years of Longitudinal Data and Segmented Regression Reveal

    by Salma Pardhan, Hanna Gyllensten, Philip Moons, Peter Eriksson, Zacharias Mandalenakis, Kok Wai Giang

    Background: Understanding long‐term health care utilization patterns in congenital heart disease (CHD) is essential for optimizing care delivery. While previous studies often assume linear trends, such assumptions could provide flawed analysis if abrupt changes in treatment or care occur, causing nonlinearity in trends. This study aims to determine if and where significant nonlinearity exists in hospitalization trends within the CHD pediatric population. Methods: Using national Swedish registers, we conducted a retrospective cohort study using segmented regression analysis of pediatric CHD health care utilization from infancy through adolescence, stratified by disease complexity. Breakpoints were identified to assess changes in trend over time, and subgroup analyses compared segmented and linear regression models. Results: Segmented regression revealed distinct utilization patterns across age groups, with highest health care use in infancy followed by a progressive decline through childhood and adolescence. Contrary to prior research, utilization declined over time regardless of CHD complexity. Identified breakpoints within the general CHD pediatric population in 1978, 1985, 1992, and 2003 aligned with key developments in CHD care. Conclusions: These findings challenge prevailing assumptions of increasing health care use over time among the pediatric CHD population. Given the identified breakpoints, caution is warranted when conducting comparative analyses that span these periods, as doing so may obscure meaningful shifts in underlying trends.

  • Open Access

    Physical fitness in adults with isolated secundum atrial septal defects

    by Linda Ashman Kröönström, Anna-Klara Zetterström, Mikael Dellborg, Åsa Cider, Peter Eriksson, Emelie Dahlin, Zacharias Mandalenakis

  • Open Access

    Morbidity Burden in Patients With Ebstein Anomaly: The Natural History

    by Filip Eckerström, Vibeke Elisabeth Hjortdal, Peter Eriksson, Mikael Dellborg, Zacharias Mandalenakis

    Background: The lifetime morbidity burden of patients with Ebstein anomaly (EA) has not been well described. Methods and Results: Through an extensive 2‐country register‐based collaboration, patients diagnosed with EA who were born between 1930 and 2017 were identified in Danish and Swedish nationwide medical registries. Each patient was matched by age and sex with 10 control subjects from the general population. Cox proportional‐hazards regression, Fine–Gray competing risk regression, and Kaplan–Meier failure function were used to estimate the morbidity burden. The study included 794 patients diagnosed with EA and 7940 controls, with a median follow‐up period of 33 years. Among patients with EA, approximately half (n=442) had isolated EA, and 28% (n=218) had concomitant atrial septal defect. Patients with complex anatomy demonstrated the highest cardiovascular morbidity burden, followed by those with concomitant atrial septal defect and isolated EA. The lifetime cumulative incidence of supraventricular arrhythmia and ventricular preexcitation in patients with EA, with or without atrial septal defect, was approximately 70% and 19%, respectively. Supraventricular arrhythmia substantially increased the risk of ischemic stroke (hazard ratio [HR] 22.6 [95% CI, 11.1–45.9]). Presence of atrial septal defect significantly affected arrhythmia and heart failure burden compared with isolated EA. In the total cohort of patients with EA, supraventricular arrhythmia onset led to an immediate high incidence of heart failure, with a 10‐year cumulative incidence of 18%. Conclusions: The natural history of EA, whether isolated or not, involves a substantial burden of cardiovascular morbidity and thus a highly vulnerable long‐term prognosis.


  • Open Access

    Ischemic Stroke in Patients With Congenital Heart Disease and Atrial Fibrillation

    by Arvid Holmgren, Kok Wai Giang, Maria Fedchenko, Peter Eriksson, Mikael Dellborg, Zacharias Mandalenakis

    Background: Atrial fibrillation (AF) is a common arrhythmia in patients with congenital heart disease (CHD), but little is known about the risk for ischemic stroke among younger patients with CHD (aged <65 years) with AF. Methods and Results: Using data from the National Swedish Patient Register and Cause of Death Register, we identified all patients with both CHD and AF born in Sweden between 1970 and 2017. The Swedish total population register was used to identify age‐ and sex‐matched patients without CHD; those with AF were used as controls. Bottos hierarchical classification was used to define CHD as either complex or noncomplex. Controls were followed from the onset of AF until the index ischemic stroke, death, or end of study (December 31, 2017). We identified 951 patients with CHD with AF and 606 controls with AF. Among patients with both CHD and AF, 2.9% of patients (n=28) developed ischemic stroke, compared with 0.5% (n=3) in controls. When adjusted for age, sex, hypertension, and heart failure, a hazard ratio (HR) of 5.16 (95% CI, 1.52–17.46) was acquired. The HR in noncomplex CHD was 3.84 (95% CI, 1.07–13.84), and the HR in complex CHD was 8.34 (95% CI, 2.27–30.57). For patients born in 1970 to 1989, the HR in ischemic stroke was 7.35 (95% CI, 1.70–31.75). No adjusted HR for patients with CHD born in 1990 to 2017 could be acquired due to few events. Conclusions: The risk for ischemic stroke may be 5 times higher in patients with both CHD and AF compared with patients without CHD with AF. However, larger studies may be needed to confirm/refute these results.


  • Open Access

    Impact of Down Syndrome on Survival Among Patients With Congenital Heart Disease

    by Stella Engsner, Kok Wai Giang, Mikael Dellborg, Maria Fedchenko, Peter Eriksson, Zacharias Mandalenakis

    Background: Increasing survival among patients with congenital heart disease (CHD) has recently been reported. However, the impact of Down syndrome (DS) in patients with CHD is still debated. We aimed to estimate survival in patients with CHD with versus without DS compared with matched controls from the general population without CHD or DS. Methods and Results: We linked data from Swedish health registries to identify patients with CHD born between 1970 and 2017. Data from the Total Population Register were used to match each patient with CHD by sex and birth year with 8 controls without CHD or DS. A Cox proportional regression model was used to estimate mortality risk, and Kaplan–Meier curves were analyzed for the survival analysis. We identified 3285 patients with CHD‐DS, 64 529 patients with CHD without DS, and 26 128 matched controls. The mortality risk was 25.1 times higher (95% CI, 21.3–29.5) in patients with CHD‐DS versus controls. The mortality rate was 2 times higher (95% CI, 1.94–2.31) for patients with CHD with versus without DS. Lower mortality was found during the second versus first birth periods in patients with CHD‐DS compared with controls; hazard ratio: 46.8 (95% CI, 29.5–74.0) and 17.7 (95% CI, 12.8–24.42) in those born between 1970 and 1989 versus 1990 and 2017, respectively. Conclusions: In this retrospective cohort study, the mortality risk among patients with CHD‐DS was 25 times higher compared with matched controls and 2 times higher compared with patients with CHD without DS. Survival was higher in patients with CHD‐DS born after versus before 1990, coinciding with the modern era of congenital heart care.


  • Open Access

    Percutaneous atrial shunt closure and the risk of recurrent ischemic stroke: A register-based, nationwide cohort study

    by Alexia Karagianni, Zacharias Mandalenakis, Savvas Papadopoulos, Mikael Dellborg, Peter Eriksson


  • Top Cited Papers
    Open Access

    Adults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age

    by Mikael Dellborg, Kok Wai Giang, Peter Eriksson, Hans Liden, Maria Fedchenko, Anders Ahnfelt, Annika Rosengren, Zacharias Mandalenakis

    Background: The survival of children with congenital heart disease has increased substantially over the past decades, with 97% currently reaching adulthood. The total effect of advanced treatment on future mortality and morbidity in adult survivors with congenital heart disease (CHD) is less well described. Methods: We used data from the Swedish National Inpatient, Outpatient, and Cause of Death Register to identify patients with CHD who were born between 1950 and 1999 and were alive at 18 years of age. Ten controls identified from the Total Population Register were matched for year of birth and sex and with each patient with CHD. Follow-up was from 1968 and 18 years of age until death or at the end of the study (2017). Survival percentage with 95% CI for all-cause mortality were performed with Kaplan-Meier survival function. Cox proportional hazard regression models with hazard ratios (HRs) and 95% CI were used to estimate the risk of all-cause mortality. Results: We included 37 278 patients with adult CHD (ACHD) and 412 799 controls. Mean follow-up was 19.2 years (±13.6). Altogether, 1937 patients with ACHD (5.2%) and 6690 controls (1.6%) died, a death rate of 2.73 per 1000 person-years and 0.84 per 1000 person years, respectively. Mortality was 3.2 times higher (95% CI, 3.0–3.4; P 75% of patients with ACHD were still alive. Mortality was highest among patients with conotruncal defects (HR, 10.13 [95% CI, 8.78–11.69]), but also significantly higher for the more benign lesions, with the lowest risk in patients with atrial septal defects (HR, 1.36 [95% CI, 1.19–1.55]). At least 75% of patients with ACHD alive at 18 years of age lived past middle age and became sexagenerians. Conclusions: In this large, nationwide, register-based cohort study of patients with ACHD surviving to 18 years of age, the risk of mortality up to 68 years of age was >3 times higher compared with matched controls without ACHD. Despite this, at least 75% of patients with CHD alive at 18 years of age lived past middle age and became sexagenerians. A notable risk decline in the mortality for patients with ACHD was seen for those born after 1975.


  • Transcatheter Intervention for Coarctation of the Aorta

    by Peter Eriksson, Jaana Pihkala, Annette S. Jensen, Gaute Dohlen, Petru Liuba, Hakan Wahlander, Gunnar Sjoberg, Joanna Hlebowicz, Eva Furenas, Elisabeth Leirgul, et al.


  • Open Access

    Survival in patients with congenital heart disease and down syndrome

    by S Engsner, K W Giang, M Dellborg, M Fedchenko, P Eriksson, Z Mandalenakis

    Background: Increasing survivorship among patients with congenital heart disease (CHD) has been reported during the past decades. However, a number of patients with CHD have an associated Down syndrome diagnosis and the long-term prognosis is still debated. Purpose: The aim of the present study was to estimate the mortality risk in CHD patients with Down syndrome compared to a matched control population without CHD. Methods: We linked data from the Swedish National Patient Register and Cause of Death Register to identify all CHD patients born between January 1970 and December 2017. Then we identified all CHD patients with Down syndrome. Each CHD patient with Down syndrome was matched for sex and birth year with eight controls without CHD or Down syndrome from the Total Population Register. A Cox proportional regression model was used to estimate the mortality risk and Kaplan Meier for survival analysis. Results: In total, 3,285 patients with CHD and Down syndrome and 26,128 matched controls were identified. During a mean follow-up of 16.0 (±12.6) years, 558 CHD patients (17%) with Down syndrome, and 198 controls (0.76%) died. CHD patients with Down syndrome had 25.1 times higher risk of mortality (Hazard ratio 25.1, 95%, confidence interval (CI) 21.3–29.5) compared with controls. Patients with the most complex CHD were found to have the highest mortality risk (Hazard ratio 32.3, 95% CI 26.1–39.9). A decrease in risk of mortality during the first year of life was found between the two birth periods, risk of mortality was 46.8 (CI 29.5–74.0) in 1970–1989 and 17.7 (CI 12.8–24.42) 1990–2017. In addition, the mortality risk was two times (95% CI 1.94–2.31) higher for CHD patients with Down syndrome when compared to CHD patients without Down syndrome. Conclusion: The risk of mortality among CHD patients with Down syndrome was 25 times higher compared to controls without CHD or Down syndrome. The highest risk of mortality was found in patients with complex CHD. The survivorship rate was exponentially increased in CHD patients with Down syndrome that were born after 1990, determining the modern era of congenital heart care. Funding Acknowledgement: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Swedish state under an agreement between the Swedish Government and county Councils (ALF)

  • Open Access

    Heart failure and long-term prognosis in patients with congenital heart disease: a nationwide, register-based cohort study

    by N Bergh, K Skoglund, M Fedchenko, E Bollano, P Eriksson, M F Dellborg, W Giang Kok, Z Mandalenakis

    Introduction: Heart failure (HF) is associated with high morbidity and severe prognosis. The aim of this study was to investigate the risk of HF in patients with congenital heart disease (CHD) and to determine the prognosis after HF diagnoses in patients with CHD compared to HF controls without CHD. Methods: We identified 89,532 patients with CHD born between 1930 and 2017 from the National Patient Register in Sweden and matched with 10 controls without CHD by gender and birth year from the National Population Register. The study population was followed-up until 2017, through the Swedish Patient Register and Cause of Death Register. Results: Altogether, 7,013 (7.8%) patients with CHD and 9,681 (1.1%) controls developed HF. The overall incidence rate of HF was 31.6 per 104 person-years in patients with CHD and 4.0 per 104 person-years in controls. The mean age for HF diagnoses was 40.3 (± 28.8) in patients with CHD and 66.4 (± 13.6) for controls. The risk for developing HF was significantly higher in complex than non-complex CHD lesion groups, HR 28.7 (26.5–31.0) and HR 6.9 (6.7–7.2) respectively. Mortality incidence rate was twice as high in controls with HF compared to CHD with HF (IR 9.7 (9.4–10.0) and 4.74 (4.6–4.9), respectively). The mortality incidence was higher within all age groups except for 18–39 years and there was no difference between complex and non complex lesions Conclusion: One out of thirteen CHD patients will develop HF. The highest risk for HF is within CHD patients with complex lesions. CHD patients develops HF at a considerably younger age, reflecting their slightly better prognosis after development of HF compared to controls with HF. Funding Acknowledgement: Type of funding sources: None.